LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, announced today that its Venezuelan operating subsidiary, LATAMEDAI VE, has entered into a memorandum of understanding (MOU) with FARMASER to develop a customized artificial intelligence and automation platform designed to support the pharmacy chain’s current operations and planned expansion.
Under the MOU, the parties will collaborate on the design, adaptation, testing, and evaluation of a software platform tailored to FARMASER’s operational requirements. The initial phase will involve defining technical and operational specifications, adapting the software to FARMASER’s pharmacy workflows, and establishing a phased development and testing process. The proposed platform is intended to include e-commerce, prescription-management, customer-service, inventory-planning, and business-analytics functions.
A key component of the collaboration is the potential integration of LataMed AI’s three artificial intelligence-supported healthcare models—CardioAI, PulmoAI, and NeuroAI—across FARMASER’s three existing pharmacy locations and up to 15 planned additional locations. These models are designed to support access to cardiovascular, pulmonary, and neurological health information and related digital health services, subject to continued development, testing, applicable regulatory requirements, and appropriate clinical and operational protocols.
LataMed AI emphasized that any prescription-related or AI-supported functionality would be designed to assist administrative, operational, and healthcare workflows and would not replace the professional judgment or responsibilities of authorized pharmacists, medical professionals, or other qualified personnel.
The parties are also evaluating an annual software licensing or subscription model for any commercial implementation of the platform. However, the scope, timing, pricing, and other terms of a commercial deployment have not yet been finalized and remain subject to successful development and testing, agreement on commercial terms, and any additional definitive documentation required by the parties.
“This memorandum of understanding represents an opportunity to apply our technology within an important part of the healthcare delivery ecosystem,” said Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp. “Pharmacies play a central role in connecting patients with medications, healthcare products, and related services. Our objective is to work with FARMASER to develop a platform that supports its current operations and planned expansion while evaluating the integration of our AI-supported healthcare technologies across its pharmacy network.”
Management believes the proposed collaboration aligns with LataMed AI’s broader strategy of developing an integrated healthcare ecosystem connecting patients, healthcare professionals, pharmacies, insurers, payment providers, and other participants in the delivery of healthcare services. The FARMASER platform would also represent a potential enterprise application of the company’s technology beyond its patient-facing telemedicine services, creating technology infrastructure that may ultimately be adaptable to other healthcare organizations throughout Latin America.
The MOU establishes a framework for cooperation but does not guarantee successful completion or commercial deployment of the platform, integration of the company’s AI-supported technologies, execution of a definitive licensing agreement, opening of additional FARMASER locations, or generation of revenue. The company will provide additional information regarding development and potential implementation as appropriate.
For more information, visit https://latamed.ai or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
